skip to main content

KEYNOTE-522 Adjuvant — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateBreast CancerKEYNOTE-522 AdjuvantSCE Medical Oncology

A 45-year-old woman with TNBC and germline BRCA1 achieves pCR after neoadjuvant pembrolizumab + chemotherapy (KEYNOTE-522). What adjuvant therapy follows surgery?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Adjuvant pembrolizumab for up to 9 cycles completing 1 year total of perioperative pembrolizumab per KEYNOTE-522 protocol

KEYNOTE-522 is perioperative: neoadjuvant pembro+chemo → surgery → adjuvant pembrolizumab (up to 9 cycles). The adjuvant phase continues regardless of pCR status.

Reference: NICE TA878; KEYNOTE-522 Schmid et al NEJM 2022